+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06712641

Comparing Gentamicin Plus Narrow Spectrum Betalactams Versus Broad Spectrum Betalactams for Empirical Treatment of Suspected Sepsis in Adults

Led by University Hospital, Akershus · Updated on 2026-10-28

1900

Participants Needed

15

Research Sites

256 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of two antibiotic treatment strategies for adults hospitalized with suspected community-acquired sepsis. The study compares empirical combination therapy using gentamicin with narrow spectrum betalactams penicillin, ampicillin, or cloxacillin against empirical therapy with broad spectrum betalactams cefotaxime or piperacillin-tazobactam. The goal is to determine if the combination therapy is as safe as broad spectrum therapy, particularly regarding kidney injury and death, while also examining its impact on antibiotic resistance and the gut microbiome. Participants are randomly assigned to receive either gentamicin plus a narrow spectrum betalactam or one of the broad spectrum betalactams as empirical treatment for suspected sepsis. Treatments are given according to hospital protocols during the initial management of sepsis. The study is designed as a pragmatic clinical trial with parallel groups and does not use blinding. The investigation spans up to 30 days after randomization for primary outcomes, with follow-up during the hospital stay and after discharge. During the study, participants are monitored for various outcomes including 30-day mortality, acute kidney injury within 30 days, duration of hospital and intensive care stays, ventilator and vasopressor therapy use, hospital readmissions, and antibiotic treatment duration. Safety and treatment effects are assessed through clinical observations and data collected during hospitalization and up to 30 days after discharge. The total participation time covers the initial hospital treatment period and the 30-day follow-up after randomization.

CONDITIONS

Brief Title

Aminoglycosides in Early Sepsis

Research Team

M

Magnus N Lyngbakken, MD PhD

K

Kristian Tonby, MD PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here